I'm hearing that we granted a 10 year exclusivity to Baxter and that they exercised their option at 90 ( great news in and of itself) !!!
But nothing specific ( yet?) about what Spectral received in return.
The net $ received are still unknown.
Go forward funding ( to complete the trial) is still a significant, top of mind item for all shareholders - or at least it should be.
Perhaps more info tomorrow !
All in all, I love the confirmed commitment from our multi-billion dollar, leading US hospital supplier, and otherwise well-connected medical community partner ( now a long term partner)
MM